Nymox Pharmaceutical Corporation Stock price
Equities
NYMXF
BSP733981026
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 USD | -4.76% | 0.00% | -32.20% |
Financials (USD)
Sales 2021 | - | Sales 2022 | - | Capitalization | 29.51M |
---|---|---|---|---|---|
Net income 2021 | -12M | Net income 2022 | -6M | EV / Sales 2021 | - |
Net cash position 2021 | 439K | Net cash position 2022 | 1.23M | EV / Sales 2022 | - |
P/E ratio 2021 |
-8.5
x | P/E ratio 2022 |
-4.39
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.95% |
1 day | -4.76% | ||
Current month | +8.84% | ||
1 month | +3.90% | ||
3 months | -31.51% | ||
6 months | -27.40% | ||
Current year | -32.20% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.4 | -4.76% | 34,405 |
24-03-27 | 0.42 | +10.94% | 22,815 |
24-03-26 | 0.3786 | +20.19% | 23,132 |
24-03-25 | 0.315 | -21.25% | 17,321 |
24-03-22 | 0.4 | 0.00% | 47,825 |
Delayed Quote OTC Markets, March 28, 2024 at 12:26 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-32.20% | 37.35M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |